NEWARK Calif. May 25 2017 PRNewswire Protagonist Therapeutics Inc. Nasdaq PTGX today announced that the company has initiated a Phase 1 clinical study of PTG300 in normal healthy volunteers. PTG300 is an injectable hepcidin mimetic peptide discovered usi...
↧